Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag for Prolonged Bone Marrow Toxicity Post-CAR-T
NCT05286164Phase 2Unknown
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- Apr 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eltrombopag in bone marrow aplasia, sponsored by Tel Aviv Sourasky Medical Center. Status: unknown.
02
Drugs
eltrombopag
03
Conditions
bone marrow aplasia
Beyond the preview
Go deeper on NCT05286164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05286164.